This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Here's Why You Should Retain STERIS (STE) Stock For Now
by Zacks Equity Research
Investors are optimistic about STERIS' (STE) robust segmental performance and upbeat 2022 guidance.
Thermo Fisher (TMO) Launches NGS Platform for Clinical Labs
by Zacks Equity Research
Thermo Fisher's (TMO) Ion Torrent Genexus Dx Integrated Sequencer makes next-generation sequencing accessible for all clinical laboratories.
Edwards Lifesciences (EW) Up 7.5% Since Q4 Earnings Release
by Zacks Equity Research
Edwards Lifesciences' (EW) stock rallies on impressive fourth-quarter performance and bullish 2022 guidance.
McKesson (MCK) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, McKesson (MCK) closed at $307, marking a -0.48% move from the previous day.
Here's Why You Should Hold on to Inogen (INGN) Stock Now
by Zacks Equity Research
Inogen (INGN) continues to benefit from strength in the direct-to-customer business model. However, rising costs remain a woe.
3 Lucrative Stocks From the Promising Dental Supplies Industry
by Trina Mukherjee
Despite the COVID-19 pandemic-induced challenges, teledentistry coupled with AI & Robotics should lend support to the Zacks Medical - Dental Supplies industry. MCK, WST and CAH are well-poised to gain from the prospects.
Here's Why You Should Hold on to Align Technology (ALGN) Now
by Zacks Equity Research
Investors are optimistic about Align Technology (ALGN) on the growing market adoption of the iTero Element 5D Plus imaging system.
Here's Why You Should Hold on to NuVasive (NUVA) Stock for Now
by Zacks Equity Research
Investors are optimistic about NuVasive's (NUVA) better-than-expected revenues and strong spine market presence.
Henry Schein (HSIC) Digital Dentistry Gains, Expands Globally
by Zacks Equity Research
Henry Schein (HSIC) witnesses strength in dental consumable merchandise sales in France, Germany, Austria, Belgium.
Alcon (ALC) Publishes Dividend, New Board Member Addition Plans
by Zacks Equity Research
Alcon's 2022 AGM is set to take place in a closed format without the personal presence of shareholders.
Here's Why You Should Hold on to DexCom (DXCM) Stock Now
by Zacks Equity Research
DexCom (DXCM) continues to benefit from a solid product portfolio and a strong international presence. However, supply constraints remain a woe.
Here's Why You Should Invest in IDEXX (IDXX) Stock for Now
by Zacks Equity Research
Investors are optimistic about IDEXX's (IDXX) strong international performances and favorable 2022 outlook.
Abbott's (ABT) CGM Device Gets MHLW Nod for Expanded Coverage
by Zacks Equity Research
Abbott's (ABT) FreeStyle Libre system will allow diabetics to get the glucose data required to manage their condition without using routine fingersticks.
McKesson (MCK) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
McKesson (MCK) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Medtronic (MDT) Completes 1st Patient Implant of Implantable TNM
by Zacks Equity Research
Medtronic's (MDT) TITAN 2 study will examine the safety and efficacy of the implantable TNM device in people with OAB.
Here's Why You Should Retain QIAGEN (QGEN) Stock for Now
by Zacks Equity Research
Investors are optimistic about QIAGEN's (QGEN) recent expansion in test menu and strategic collaborations.
Neogen's (NEOG) Q3 Earnings Miss Estimates, Margins Down
by Zacks Equity Research
Robust segmental performance and contributions from the Soleris product line drive the top line for Neogen (NEOG) in third-quarter of fiscal 2022 results.
Here's Why You Should Retain Globus Medical (GMED) Stock Now
by Zacks Equity Research
Investors are optimistic about Globus Medical's (GMED) better-than-expected results and strength in the U.S. Spine business.
Phibro (PAHC) Rises 6.1% Since Q2 Earnings: What's Driving It?
by Zacks Equity Research
Investors are optimistic about Phibro's (PAHC) booming vaccine business and strong global presence.
National Vision (EYE) Hurt by Rising Costs, Vendor Dependency
by Zacks Equity Research
High dependence on a limited number of suppliers exposes National Vision (EYE) to supplier concentration risk.
Why Holding Humana (HUM) in Your Portfolio is a Prudent Move
by Zacks Equity Research
Banking on better membership and strategic initiatives, Humana (HUM) holds immense potential to reap benefits for investors.
Here's Why You Should Hold on to Thermo Fisher (TMO) Stock Now
by Zacks Equity Research
Investors are optimistic about Thermo Fisher (TMO) on its progress with COVID-19-related products and services.
Quest Diagnostics' (DGX) Volumes Aid, Price Pressure Stays
by Zacks Equity Research
According to Quest Diagnostics (DGX), the delay of the 2022 PAMA cuts announced last year proved beneficial for the industry and Medicare beneficiaries.
QIAGEN (QGEN) QuantiFeron Hits New Sales Landmark in TB Testing
by Zacks Equity Research
According to QIAGEN (QGEN), QuantiFERON is different from other IGRA tests based on its efficient workflow.
Quest Diagnostics' (DGX) New Contract to Aid COVID-19 Research
by Zacks Equity Research
Quest Diagnostics' (DGX) COVID-19 serological tests, nationwide reach and data analytics capabilities will help assess COVID-19 vulnerability throughout the country.